Clay Siegall – a Researcher and an Entrepreneur in Cancer Therapies

Seattle Genetics is a creation of Dr. Clay Siegall. He founded it in 1998 and currently runs it as the CEO. Clay’s aim is to lead the company to great heights in the therapy industry. The company developed FDA-approved antibody drug which was the first. They started with a few researchers and now is an important player in cancer research.

Dr. Clay Siegall narrates of how he developed an interest in the different forms of cancer treatment due to his passion for helping patients and also his prior experience in drug development practices. Money was also another drive to starting the business though this was not the major reason. He also reasoned on how the profits and patents bounced back to his employer, Bristol, where he was a senior researcher. He wanted to be his boss.

At Seattle Genetics, Clay says that they make money by selling drugs, especially the first approved FDA drug. This drug makes a lot of money for the company. It was, however, a long and expensive process of having the drug approved where they had to foot all the bills for the process expenses. He says that it took the company ten years to become profitable.

Dr. Clay further explains that his team is made up of professionals. For instance, his sales team have backgrounds in biotechnology and understand his company business. The products are unique therefore standing out in the market.

His other way of making business is by spending time in meetings negotiating. He has a great legal team that does this. He exclaims that his hard work and passion to work intensely has made him succeed. He also insisted on the importance of networking and going to good schools.

About Clay Siegall

Dr. Clay Siegall is the Founder, President, and CEO of Seattle Genetics. He is also the Chairman of the Board of Directors of the Company. He has a degree in Zoology, which he received from the University of Maryland. Clay’s other notable educational milestone is a Ph.D. in Genetics having graduated from George Washington University. He is a scientist emphasizing in cancer therapies.

Under his leadership, Seattle Genetics has a diverse pipeline of ADCs for cancer treatment. He has also led the company to gain multiple licenses for ADC technology. He has led the company’s capital-raising activities.